Genetic Predisposition to Poor Opioid Response in Preterm Infants: Impact of KCNJ6 and COMT Polymorphisms on Pain Relief after Endotracheal Intubation

Therapeutic Drug Monitoring

Volumn 38, Issue 4, 2016, Pages 525-533

  Elens, Laure ^a,b   Norman, Elisabeth ^c   Matic, Maja ^a   Rane, Anders ^d   Fellman, Vineta ^c,e   Van Schaik, Ron H N ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^c LUND UNIVERSITY   (Sweden)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^e UNIVERSITY OF HELSINKI   (Finland)

Author keywords

catechol O methyl transferase; opioids; pain; pharmacogenetics; potassium inwardly rectifying channel subfamily J member 6

Indexed keywords

CATECHOL METHYLTRANSFERASE; KCNJ6 PROTEIN; MORPHINE; PROTEIN; REMIFENTANIL; UNCLASSIFIED DRUG; COMT PROTEIN, HUMAN; G PROTEIN COUPLED INWARDLY RECTIFYING POTASSIUM CHANNEL; KCNJ6 PROTEIN, HUMAN; NARCOTIC ANALGESIC AGENT; PIPERIDINE DERIVATIVE;

ALLELE; ANALGESIA; ARTICLE; BIRTH WEIGHT; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOTRACHEAL INTUBATION; FEMALE; FOLLOW UP; GENE FREQUENCY; GENETIC PREDISPOSITION; GENOTYPE; GESTATIONAL AGE; HUMAN; MALE; NEWBORN; PAIN ASSESSMENT; PREMATURITY; PREMEDICATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE; GENETICS; PAIN; PAIN MEASUREMENT; PROCEDURES;

ALLELES; ANALGESICS, OPIOID; CATECHOL O-METHYLTRANSFERASE; G PROTEIN-COUPLED INWARDLY-RECTIFYING POTASSIUM CHANNELS; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; INTUBATION, INTRATRACHEAL; MORPHINE; PAIN; PAIN MANAGEMENT; PAIN MEASUREMENT; PIPERIDINES; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84961901852     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0000000000000301     Document Type: Article

References (41)

1. Walker SM. Neonatal pain. Paediatr Anaesth. 2014;24:39-48
2. Sanders RD, Ma D, Brooks P, et al. Balancing paediatric anaesthesia: preclinical insights into analgesia, hypnosis, neuroprotection, and neurotoxicity. Br J Anaesth. 2008;101:597-609
3. Sanders RD, Hassell J, Davidson AJ, et al. Impact of anaesthetics and surgery on neurodevelopment: an update. Br J Anaesth. 2013;110(suppl 1):i53-i72
4. Allegaert K, Tibboel D, van den Anker J. Pharmacological treatment of neonatal pain: in search of a new equipoise. Semin Fetal Neonatal Med. 2013;18:42-47
5. Carbajal R, Eble B, Anand KJ. Premedication for tracheal intubation in neonates: confusion or controversy? Semin Perinatol. 2007;31:309-317
6. Andersen S, Skorpen F. Variation in the COMT gene: implications for pain perception and pain treatment. Pharmacogenomics. 2009;10: 669-684
7. Muralidharan A, Smith MT. Pain, analgesia and genetics. J Pharm Pharmacol. 2011;63:1387-1400
8. Lacroix-Fralish ML, Ledoux JB, Mogil JS. The pain genes database: an interactive web browser of pain-related transgenic knockout studies. Pain. 2007;131:e1-e4
9. Lotsch J, Pruss H, Veh RW, et al. A KCNJ6 (Kir3.2, GIRK2) gene polymorphism modulates opioid effects on analgesia and addiction but not on pupil size. Pharmacogenet Genomics. 2010;20:291-297
10. Blednov YA, Stoffel M, Alva H, et al. A pervasive mechanism for analgesia: activation of GIRK2 channels. Proc Natl Acad Sci U S A. 2003;100:277-282
11. Marker CL, Cintora SC, Roman MI, et al. Hyperalgesia and blunted morphine analgesia in G protein-gated potassium channel subunit knockout mice. Neuroreport. 2002;13:2509-2513
12. Marker CL, Lujan R, Loh HH, et al. Spinal G-protein-gated potassium channels contribute in a dose-dependent manner to the analgesic effect of mu-and delta-but not kappa-opioids. J Neurosci. 2005;25:3551-3559
13. Marker CL, Stoffel M, Wickman K. Spinal G-protein-gated K+ channels formed by GIRK1 and GIRK2 subunits modulate thermal nociception and contribute to morphine analgesia. J Neurosci. 2004;24:2806-2812
14. Mitrovic I, Margeta-Mitrovic M, Bader S, et al. Contribution of GIRK2-mediated postsynaptic signaling to opiate and alpha 2-adrenergic analgesia and analgesic sex differences. Proc Natl Acad Sci U S A. 2003;100: 271-276
15. Nishizawa D, Nagashima M, Katoh R, et al. Association between KCNJ6 (GIRK2) gene polymorphisms and postoperative analgesic requirements after major abdominal surgery. PLoS One. 2009;4:e7060
16. Diatchenko L, Slade GD, Nackley AG, et al. Genetic basis for individual variations in pain perception and the development of a chronic pain condition. Hum Mol Genet. 2005;14:135-143
17. Emin Erdal M, Herken H, Yilmaz M, et al. Significance of the catechol-O-methyltransferase gene polymorphism in migraine. Brain Res Mol Brain Res. 2001;94:193-196
18. Gursoy S, Erdal E, Herken H, et al. Significance of catechol-Omethyltransferase gene polymorphism in fibromyalgia syndrome. Rheumatol Int. 2003;23:104-107
19. Vargas-Alarcon G, Fragoso JM, Cruz-Robles D, et al. Catechol-O-methyltransferase gene haplotypes in Mexican and Spanish patients with fibromyalgia. Arthritis Res Ther. 2007;9:R110
20. Ahlers SJ, Elens LL, van Gulik L, et al. The Val158Met polymorphism of the COMT gene is associated with increased pain sensitivity in morphine-treated patients undergoing a painful procedure after cardiac surgery. Br J Clin Pharmacol. 2013;75:1506-1515
21. Diatchenko L, Nackley AG, Slade GD, et al. Catechol-O-methyltransferase gene polymorphisms are associated with multiple pain-evoking stimuli. Pain. 2006;125:216-224
22. Jensen KB, Lonsdorf TB, Schalling M, et al. Increased sensitivity to thermal pain following a single opiate dose is influenced by the COMT val(158)met polymorphism. PLoS One. 2009;4:e6016
23. Loggia ML, Jensen K, Gollub RL, et al. The catechol-Omethyltransferase (COMT) val158met polymorphism affects brain responses to repeated painful stimuli. PLoS One. 2011;6:e27764
24. Zubieta JK, Heitzeg MM, Smith YR, et al. COMT val158met genotype affects mu-opioid neurotransmitter responses to a pain stressor. Science. 2003;299:1240-1243
25. Matsuoka H, Arao T, Makimura C, et al. Expression changes in arrestin beta 1 and genetic variation in catechol-O-methyltransferase are biomarkers for the response to morphine treatment in cancer patients. Oncol Rep. 2012;27:1393-1399
26. Rakvag TT, Klepstad P, Baar C, et al. The Val158Met polymorphism of the human catechol-O-methyltransferase (COMT) gene may influence morphine requirements in cancer pain patients. Pain. 2005;116:73-78
27. Lachman HM, Papolos DF, Saito T, et al. Human catechol-Omethyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders. Pharmacogenetics. 1996;6:243-250
28. Lotta T, Vidgren J, Tilgmann C, et al. Kinetics of human soluble and membrane-bound catechol O-methyltransferase: a revised mechanism and description of the thermolabile variant of the enzyme. Biochemistry. 1995;34:4202-4210
29. Norman E, Wikstrom S, Hellstrom-Westas L, et al. Rapid sequence induction is superior to morphine for intubation of preterm infants: a randomized controlled trial. J Pediatr. 2011;159:893-899.e891
30. Lundqvist P, Kleberg A, Edberg AK, et al. Development and psychometric properties of the Swedish ALPS-Neo pain and stress assessment scale for newborn infants. Acta Paediatr. 2014;103:833-839
31. Ikeda K, Kobayashi T, Kumanishi T, et al. Involvement of G-proteinactivated inwardly rectifying K (GIRK) channels in opioid-induced analgesia. Neurosci Res. 2000;38:113-116
32. Bai HW, Shim JY, Yu J, et al. Biochemical and molecular modeling studies of the O-methylation of various endogenous and exogenous catechol substrates catalyzed by recombinant human soluble and membrane-bound catechol-O-methyltransferases. Chem Res Toxicol. 2007;20:1409-1425
33. Millan MJ. Descending control of pain. Prog Neurobiol. 2002;66:355-474
34. Wood PB. Role of central dopamine in pain and analgesia. Expert Rev Neurother. 2008;8:781-797
35. Kim H, Lee H, Rowan J, et al. Genetic polymorphisms in monoamine neurotransmitter systems show only weak association with acute postsurgical pain in humans. Mol Pain. 2006;2:24
36. Kim H, Neubert JK, San Miguel A, et al. Genetic influence on variability in human acute experimental pain sensitivity associated with gender, ethnicity and psychological temperament. Pain. 2004;109: 488-496
37. Klepstad P, Fladvad T, Skorpen F, et al. Influence from genetic variability on opioid use for cancer pain: a European genetic association study of 2294 cancer pain patients. Pain. 2011;152:1139-1145
38. Hwang IC, Park JY, Myung SK, et al. OPRM1 A118G gene variant and postoperative opioid requirement: a systematic review and meta-analysis. Anesthesiology. 2014;121:825-834
39. Enabah D, El Baz H, Moselhy H. Higher frequency of C.3435 of the ABCB1 gene in patients with tramadol dependence disorder. Am J Drug Alcohol Abuse. 2014;40:317-320
40. Wang XS, Song HB, Chen S, et al. Association of single nucleotide polymorphisms of ABCB1, OPRM1 and COMT with pain perception in cancer patients. J Huazhong Univ Sci Technolog Med Sci. 2015;35:752-758
41. Xu GH, Gao M, Sheng QY, et al. Opioid receptor A118G polymorphism does not affect the consumption of sufentanil and ropivacaine by patientcontrolled epidural analgesia after cesarean section. Ther Drug Monit. 2015;37:53-57